A Phase 3 interventional study of Mirabegron in Overactive Bladder and Urinary Incontinence, sponsored by CHU de Quebec-Universite Laval. Completed. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2018-04-24.
Sponsored by CHU de Quebec-Universite Laval · Phase 3, Interventional, and Treatment
The objective is to evaluate the efficacy and safety of adding mirabegron to an antimuscarinic to treat urinary incontinence in children with Overactive Bladder that are refractory to antimuscarinics.
Overactive bladder (OAB) is a highly prevalent disorder in the pediatric population. This condition comprises many urinary symptoms, such as urgency, increased daytime frequency of micturition, urge incontinence and nocturia. These symptoms are especially troublesome for the pediatric patients and their family since it causes embarrassment and it limits everyday activities and impairs children's development. Furthermore, serious complications are seen if this condition is not treated properly, as urinary tract infection, vesico-ureteral reflux and dysfunctional voiding. Antimuscarinic agents are the current pharmacologic mainstay for OAB. Many side effects are reported with the clinical use of antimuscarinics. Oxybutynin is the most widely antimuscarinic agent used in the pediatric population and is the only molecule approved by Health Canada for children with OAB. However, some patients have a suboptimal response to antimuscarinic and many experience side effects. Children with OAB therefore represent a disease population with a need for an alternative effective, safe and well-tolerated therapy to help manage the overactive detrusor, reducing or preventing incontinence.
Mirabegron, a β3-adrenoceptor (β3-AR) agonist approved for the treatment of OAB symptoms in the adult population, is the first of a new class of compounds with a different mechanism of action. The recommended starting dose of mirabegron is 25mg, which can be increased to 50mg, based on individual efficacy and tolerability. Side effects commonly reported with antimuscarinics were not observed more often with mirabegron than with placebo (headache 2.0%, dry mouth 2.0%, constipation 1.6%). Several Phase II and III studies have shown significant improvement in clinical OAB symptoms in adults treated with mirabegron with a favorable tolerability profile. Mirabegron has not been studied yet for pediatric patients and no recommendation with regards to its use has been issued by the manufacturer nor medical regulatory bodies.
A prospective open-label study, using an adjusted-dose regimen of mirabegron (25-50mg) added to the existing antimuscanic treatment (dual treatment), including pediatric patients with refractory urinary incontinence due to OAB. This protocol was approved by the investigators' research ethics board. Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. Pprimary end-point is efficacy toward urinary continence and secondary end-points are tolerability and safety. The patients/parents satisfaction will also be recorded.
After 8 to 12 weeks on the new medication, the possibility of up-titration will be assessed. Patients and parents will be questioned on compliance, tolerability and efficacy. If the patient is taking the medication ≥80% of the time, does not have any significant side effects and still has significant OAB symptoms, the investigators will offer a dose increase (Mirabegron 50mg daily). If accepted, the medication will be provided with instructions to report any new side effects.
Subjects will complete a 3-day voiding diary prior to each medical visit to assess the efficacy of the treatment and urotherapy. Visits will be done every 3 months.
1,363 studies on the registry are indexed under Urinary Incontinence; 228 are open to participants now.
This study's enrollment of 35 is below the median of 66 across 1,011 interventional studies indexed under Urinary Incontinence.
Browse Urinary Incontinence studies →CHU de Quebec-Universite Laval is the lead sponsor of 134 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Experimental: Add-on Mirabegron Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. They will keep the antimuscarinic and Mirabegron will be added (dual therapy).
Drug: Mirabegron
Patients will keep the antimuscarinic providing some efficacy and that is tolerated and Mirabegron will be added (dual therapy).
Also known as: Myrbetriq
Response to Urinary Incontinence as a Composite Measure of Efficacy of add-on Mirabegron
Results were based on the International Children's Continence Sociéty classification. Parents or patients supervised by their parents rated symptom relief on a questionnaire as complete cure (definied as dryness) or partial response (reduction of 50% to 99% in incontinence episodes).
Time frame: up to 52 weeks
Number of Participants With Grade 2 or 3 Urgency Episodes as a Measure of Efficacy
On voiding diary, participants described their urgency according to the Canadian Urological Association voiding diary, range 0 to 3 at study entry and at study end.
Time frame: up to 52 weeks
Number of Participants With Cardio Vascular Safety
Cardiovascular safety: mean difference in blood pressure (Variation in blood pressure: systolic ±20 mmHg, diastolic ±15 mmHg), blood pressure was taken at each visit and at the study end.
Time frame: Participants will be followed for the duration of the study, up to 52 weeks
Number of Participants Showing Improved Quality of Life Using the Patient Perception of Bladder Condition Scale and Voiding Diaries
Effectiveness will also be assessed using the Patient Perception of Bladder Condition (PPBC) scale on a 6-point scale ranging from 1 to 6 ( 1 is the best score and 6 is the worst score), at study initiation, every visit and at the study end. Results will be documented based on subjective relief of symptoms and objective voiding diaries. Participants perception of bladder condition score at initiation of treatment was:4 and at last follow up score was: 2.
Time frame: Participants will be followed for the duration of the study, up to 52 weeks
Number of Participants Without Variation in Heart Rate
Cardiovascular safety: mean difference in heart rate (with variation in heart rate increase of more than 20%). Heart rate was taken at initiation of study drug, at each visit and at the study end.
Time frame: Participants will be followed for the duration of the study, up to 52 weeks
| Milestone | Add-on Mirabegron |
|---|---|
| Started | 35 |
| Completed | 33 |
| Not completed | 2 |
| Withdrew: Adverse event | 2 |
Results were based on the International Children's Continence Sociéty classification. Parents or patients supervised by their parents rated symptom relief on a questionnaire as complete cure (definied as dryness) or partial response (reduction of 50% to 99% in incontinence episodes).
| Participants | Add-on Mirabegron |
|---|---|
| Complete response:100%improvement of incontinence | 12 |
| Partial response: 50 to 99 % reduction | 23 |
On voiding diary, participants described their urgency according to the Canadian Urological Association voiding diary, range 0 to 3 at study entry and at study end.
| Participants | Add-on Mirabegron |
|---|---|
| Participants with urgency 2-3 at entry | 32 |
| Participants without urgency2-3 at week 52studyend | 19 |
Cardiovascular safety: mean difference in blood pressure (Variation in blood pressure: systolic ±20 mmHg, diastolic ±15 mmHg), blood pressure was taken at each visit and at the study end.
| Participants | Add-on Mirabegron |
|---|---|
| No variation:systolic ±20 mmHg in blood pressure | 35 |
| No variation:Diastolic ±15 mmHg in blood pressure | 35 |
Effectiveness will also be assessed using the Patient Perception of Bladder Condition (PPBC) scale on a 6-point scale ranging from 1 to 6 ( 1 is the best score and 6 is the worst score), at study initiation, every visit and at the study end. Results will be documented based on subjective relief of symptoms and objective voiding diaries. Participants perception of bladder condition score at initiation of treatment was:4 and at last follow up score was: 2.
| Participants | Add-on Mirabegron |
|---|---|
| Number of Participants Showing Improved Quality of Life Using the Patient Perception of Bladder Condition Scale and Voiding Diaries | 35 |
Cardiovascular safety: mean difference in heart rate (with variation in heart rate increase of more than 20%). Heart rate was taken at initiation of study drug, at each visit and at the study end.
| Participants | Add-on Mirabegron |
|---|---|
| Number of Participants Without Variation in Heart Rate | 35 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Add-on Mirabegron | — | 0/35 (0%) | 5/35 (14.3%) |
| Event | Add-on Mirabegron |
|---|---|
| Transcient constipationGastrointestinal disorders | 2/35 |
| Abdominal colicGastrointestinal disorders | 1/35 |
| Temporary blurred visionEye disorders | 1/35 |
| RhinitisGeneral disorders | 1/35 |
| Age, Categorical(Participants) | Add-on Mirabegron |
|---|---|
| <=18 years | 35 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Add-on Mirabegron |
|---|---|
| Female | 7 |
| Male | 28 |
| Race and Ethnicity Not Collected(Participants) | Add-on Mirabegron |
|---|
| Region of Enrollment(Participants) | Add-on Mirabegron |
|---|---|
| Canada | 35 |
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CHU de Quebec-Universite Laval